[{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"c64e5bc4-4269-4e29-8344-c838b81cc443","acronym":"Pediatric AML","url":"https://clinicaltrials.gov/study/NCT05622591","created_at":"2022-11-18T14:59:38.203Z","updated_at":"2024-07-02T16:35:26.706Z","phase":"Phase 1","brief_title":"ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML","source_id_and_acronym":"NCT05622591 - Pediatric AML","lead_sponsor":"Elucida Oncology","biomarkers":" CBFA2T3 • GLIS2","pipe":"","alterations":" ","tags":["CBFA2T3 • GLIS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELU001"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-12-08"},{"id":"f51c3ecd-a431-4fc0-8ad8-bef6f1f0a08c","acronym":"T-allo10","url":"https://clinicaltrials.gov/study/NCT03198234","created_at":"2021-01-18T15:46:13.978Z","updated_at":"2024-07-02T16:35:51.038Z","phase":"Phase 1","brief_title":"Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders","source_id_and_acronym":"NCT03198234 - T-allo10","lead_sponsor":"Roncarolo, Maria Grazia, MD","biomarkers":" KMT2A • NUP98 • CBFA2T3 • GLIS2 • KDM5A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A • NUP98 • CBFA2T3 • GLIS2 • KDM5A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/30/2017","start_date":" 08/30/2017","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-04-10"}]